Overview

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

Status:
Completed
Trial end date:
2020-09-22
Target enrollment:
Participant gender:
Summary
To evaluate the long term safety of repeat dose OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Ocular Therapeutix, Inc.
Treatments:
Travoprost